Manages elevated serum phosphorus levels. ANDA 206868, held by Invagen Pharms. Lanthanum Carbonate.
As of Nov 16, 2026, ANDA 206868 (Lanthanum Carbonate), held by Invagen Pharms, was first approved by FDA on Jan 24, 2022, with 2 approved supplements and 0 published complete response letters.
Lanthanum carbonate chewable tablets are phosphate binder indicated to reduce serum phosphate in patients with end- stage renal disease (ESRD). Management of elevated serum phosphorus levels in patients with ESRD usually includes all of the following: reduction in dietary intake of phosphate, removal of phosphate by dialysis, and reduction of intestinal phosphate absorption with phosphate binders.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 24, 2022 | Original application | Approved | None posted |
| Lanthanum CarbonateEQ 500MG BASE · tablet, chewable;oral | Lanthanum Carbonate | Rx |
| Lanthanum CarbonateEQ 750MG BASE · tablet, chewable;oral | Lanthanum Carbonate | Rx |
| Lanthanum CarbonateEQ 1GM BASE · tablet, chewable;oral | Lanthanum Carbonate | Rx |
| Jan 31, 2025 | Supplement 5Labeling · Standard review | Approved | None posted |
| Dec 6, 2023 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jan 24, 2022 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters